Google News • 1/9/2026 – 1/10/2026
A key scientist from the Baby KJ team has launched a startup focused on scaling personalized CRISPR medicines. The startup aims to capitalize on the FDA's new framework for bespoke drug therapies, betting that regulators will ease up on gene-editing.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.








